Omnicom Health Group has announced the launch of CDM in Japan, a joint venture between CDM and FleishmanHillard, the country’s largest and most diversified foreign-owned multinational PR agency.
CDM has a strong focus on leading global and regional business and will assist domestically headquartered Japanese pharmaceutical enterprises to create and radiate healthcare communications to their affiliates, prescribers, and patients in outside markets.
Alongside the CDM Tokyo launch, FleishmanHillard Japan is also forming a healthcare-dedicated PR division. These two entities will share the same space, and work in close cooperation to serve the total healthcare communication needs of the Japanese market.
Ed Wise, CEO of Omnicom Health Group, said: “This marriage of world-class creativity and business acumen will enable CDM Tokyo to address the internal and consumer-facing communication needs of Japanese pharmaceutical manufacturers in addition to providing solutions across mergers & acquisitions, public affairs, and crisis management.”
Omnicom believes that Japan is at a pivot point, with drivers of the shift including major reforms of Japanese pharmaceutical approval regulations, leading to near-simultaneous launch of drugs offered by multinational pharmaceutical manufacturers. The firm also believes that the 2020 Tokyo Olympics will see a greater government and societal push for globalisation among Japanese business leaders.
Meanwhile Japan’s status as the world’s 2nd largest pharmaceutical market, with four of the top 25 pharma companies headquartered domestically, is likely to be enhanced as firms such as Takeda, Daiichi Sankyo, and Otsuka target global markets.